Karl Insogna is an Endocrinology/Metabolic physician affiliated with Yale University. OpenAlex indexes 332 publications with 21,904 citations (h-index 78); ClinicalTrials.gov lists 5 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Endocrinology, Diabetes & Metabolism profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Examining the Effect of Burosumab on Muscle Function
Sponsor: Yale University
- Calcitonin for Treating X-linked Hypophosphatemia
Sponsor: Yale University
- The Effect of Protein on Calcium Absorption and Gastric Acid Production
Sponsor: Yale University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
7 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
100%Parathyroid Hormone Analog100%Forteo100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
17 NIH research awards on record, funded 1989–2026 per NIH RePORTER. The latest:
- Different Roles for Colony Stimulating Factor 1 Isoforms in Anabolic Therapy for Low Bone Mass
Yale University
FY2026$626,333R01AR081074 - Different Roles for Colony Stimulating Factor 1 Isoforms in Anabolic Therapy for Low Bone Mass
Yale University
FY2025$639,521R01AR081074 - Different Roles for Colony Stimulating Factor 1 Isoforms in Anabolic Therapy for Low Bone Mass
Yale University
FY2024$639,520R01AR081074
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism
Journal of Bone and Mineral Research
2020
Similar KOLs
Other experts from the same institution or the same specialty.
John Krystal, MD
Yale University
Lajos Pusztai, MD
Yale University
Lee Schwamm, MD
Yale University
Naftali Kaminski, MD
Yale University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”